Moderna (MRNA) ended the recent trading session at $31.25, demonstrating a -2.95% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna said on Friday it is cancelling plans to build a messenger RNA manufacturing plant in Japan due to "changes in the ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

DelveInsight's, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline ...

The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing ...

Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna on June 30. The company’s shares closed yesterday at $28.69. Foroohar covers the Healthcare sector, focusing on stocks such ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.